Literature DB >> 14663653

Effects of chronic haloperidol and clozapine treatment on AMPA and kainate receptor binding in rat brain.

A Schmitt1, B May, B Müller, A Jatzko, G Petroianu, D F Braus, F A Henn.   

Abstract

BACKGROUND: Alterations in AMPA and kainate receptor binding have been revealed in post-mortem schizophrenic brains. As most patients had been treated with antipsychotics, medication effects cannot be excluded as a possible explanation for these results.
METHODS: Within the framework of this animal study, we investigated [3H]AMPA and [3H]kainate receptor binding in different rat brain regions following 6 months of oral treatment with either haloperidol (1.5 mg/kg/day) or clozapine (45 mg/kg/day).
RESULTS: AMPA receptor binding was increased after haloperidol treatment in the striatum, nucleus accumbens, cingulate cortex, and insular cortex. Clozapine showed increased AMPA receptor binding only in the anterior cingulate cortex. Kainate receptor binding was increased by both drugs in all hippocampal subfields.
CONCLUSIONS: This altered receptor binding may be related to beneficial neuroleptic effects and side effects. Furthermore, neuroleptic therapy may contribute to some of the post-mortem findings in the striatum in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14663653     DOI: 10.1055/s-2003-45116

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  7 in total

Review 1.  Multifunctional pharmacotherapy: what can we learn from study of selective serotonin reuptake inhibitor augmentation of antipsychotics in negative-symptom schizophrenia?

Authors:  Henry Silver; Yael Chertkow; Orly Weinreb; Lena Danovich; Moussa Youdim
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

2.  Effects of typical and atypical antipsychotic drugs on rat brain muscarinic receptors.

Authors:  Katerina Zavitsanou; Vu H Nguyen; Mei Han; Xu Feng Huang
Journal:  Neurochem Res       Date:  2007-03       Impact factor: 3.996

3.  A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.

Authors:  Donald C Goff; J Steven Lamberti; Andrew C Leon; Michael F Green; Alexander L Miller; Jayendra Patel; Theo Manschreck; Oliver Freudenreich; Steven A Johnson
Journal:  Neuropsychopharmacology       Date:  2007-05-09       Impact factor: 7.853

Review 4.  Molecular mechanisms underlying synergistic effects of SSRI-antipsychotic augmentation in treatment of negative symptoms in schizophrenia.

Authors:  Yael Chertkow; Orly Weinreb; Moussa B H Youdim; Henry Silver
Journal:  J Neural Transm (Vienna)       Date:  2009-07-04       Impact factor: 3.575

5.  Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brain.

Authors:  G Ceresoli-Borroni; A Rassoulpour; H-Q Wu; P Guidetti; R Schwarcz
Journal:  J Neural Transm (Vienna)       Date:  2006-02-09       Impact factor: 3.575

6.  Differential alterations of kainate receptor subunits in inhibitory interneurons in the anterior cingulate cortex in schizophrenia and bipolar disorder.

Authors:  Tsung-Ung W Woo; Kevin Shrestha; Christopher Amstrong; Martin M Minns; John P Walsh; Francine M Benes
Journal:  Schizophr Res       Date:  2007-08-14       Impact factor: 4.939

Review 7.  TNF-Mediated Homeostatic Synaptic Plasticity: From in vitro to in vivo Models.

Authors:  Renu Heir; David Stellwagen
Journal:  Front Cell Neurosci       Date:  2020-09-30       Impact factor: 5.505

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.